Results 21 to 30 of about 643 (132)
Frontiers in Pharmacology, 2020 Bictegravir (BIC) and tenofovir alafenamide fumarate (TAF), two potent anti-HIV drugs, had been nanoformulated (nBIC-TAF) to achieve once-a-month PrEP coverage. In-vivo mouse experiments for nBIC-TAF exhibited favorable subcutaneous (SC) pharmacokinetics.
Simone Perazzolo +3 more
doaj +1 more source
The Inflation Reduction Act: A boon for the generic and biosimilar industry
Journal of Clinical Pharmacy and Therapeutics, Volume 47, Issue 11, Page 1738-1751, November 2022., 2022 The Inflation Reduction Act gives a significant boost to generics and biosimilars!Soon lowered out‐of‐pocket costBiosimilars promoted and adopted Abstract What is Known and Objective After more than a year of negotiation, a $740 billion climate and health care bill known as The Inflation Reduction Act (IRA) became law on 16 August 2022.
Sarfaraz K. Niazi
wiley +1 more source
Cancer Reports, Volume 5, Issue 10, October 2022., 2022 Abstract Background Patients with HIV (PHIV) are living longer with the adoption of anti‐retroviral therapy. As such, more patients are presenting with advanced cancer diagnoses, including peritoneal surface malignancies. The objective of this study was to assess the safety of CRS/HIPEC in this cohort of patients.
Anna Coghill +6 more
wiley +1 more source
, 2023 HIV-1 infection is a global health issue. In the past few years, antiretroviral (ARV) drugs has been the common drugs for the treatment of HIV-1. At present, the commonly used daily oral drugs often appear in triple or double combination, which requires ...
ShengNan Zhao, Wenjing Wang
core +1 more source
Open Forum Infectious Diseases, 2023 Abstract Background Dolutegravir/lamivudine(DTG/3TC) is a complete regimen, approved by the FDA for the treatment of HIV-1 infection in treatment-naïve or virologically suppressed patients with no prior virologic failure or resistance to DTG/3TC.
Slim, Jihad +5 more
openaire +1 more source
Clinical Pharmacology &Therapeutics, Volume 110, Issue 5, Page 1231-1239, November 2021., 2021 Bictegravir is equally metabolized by cytochrome P450 (CYP)3A and uridine diphosphate‐glucuronosyltransferase (UGT)1A1. Drug–drug interaction (DDI) studies were only conducted for strong inhibitors and inducers, leading to some uncertainty whether moderate perpetrators or multiple drug associations can be safely coadministered with bictegravir. We used
Felix Stader +2 more
wiley +1 more source
The effect of changing to Bictegravir on lipids using real world data: A brief report [PDF]
, 2022 What is known and objective: Cardiovascular disease is of increasing concern in patients living with HIV. The significant advancement in antiretroviral treatment has ensured that patients are now succumbing to traditional diseases of ageing.
Hughes, Elen +4 more
core +1 more source
HIV/AIDS: Research and Palliative Care, 2023 Jenna E Januszka, Emily N Drwiega, Melissa E Badowski University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USACorrespondence: Melissa E Badowski, Clinical Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, College ...
Januszka JE, Drwiega EN, Badowski ME
doaj
Infection and Drug Resistance, 2021 Hui-Min Chang,1– 3 Pei-Yun Chou,4,5 Chen-Hsi Chou,2 Hung-Chin Tsai4– 6 1Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 2Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung ...
Chang HM, Chou PY, Chou CH, Tsai HC
doaj
2489. Adverse Events with Biktarvy: Post-Marketing Study
Open Forum Infectious Diseases, 2019 Abstract Background Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) was FDA approved in February 2018. There are no published post-marketing data evaluating safety and efficacy. After large uptake of BIC/FTC/TAF at our institution, reports of rash prompted a real-world review.
Hayes, Edwin +5 more
openaire +1 more source